BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.84 CNY | +1.22% |
|
+2.54% | -21.64% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.84
CNY
Average target price
44
CNY
Spread / Average Target
+47.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.64% | 637M | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- 603590 Stock
- News Beijing Konruns Pharmaceutical Co.,Ltd.
- Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment
